Methyl jasmonate reduces testosterone-induced benign prostatic hyperplasia through regulation of inflammatory and apoptotic processes in rats - 14/11/17
, Olubukola Oyebimpe Akanni a, Olusoji John Abiola b, Solomon Eduviere Owumi c, Oluyemi Akinloye d, Emiola Olubunmi Olapade-olaopa eBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 11 |
| Iconographies | 12 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Background |
Phytotherapy is becoming a treatment option in management of diseases including benign prostatic hyperplasia (BPH). We have shown previously that methyl jasmonate (MeJA) ameliorated BPH, however the underlying mechanism of action remains unknown. This study was designed to investigate in mechanistic terms the protective role of MeJA in BPH.
Methods |
BPH was induced by daily injections of testosterone propionate (TP) (3mg/kg) for 28 days.
Results |
The weight and organo-somatic weight of prostate in BPH rats were 6.8 and 5.1 times higher than castrated-control group, respectively. Inflammatory markers; prostatic myeloperoxidase and total nitric oxide were significantly increased in BPH group. The activity of aniline hydroxylase (Phase I drug metabolizing enzyme) was significantly increased in BPH rats by 22%. In BPH group, immuno-histochemistry revealed strong expression of prostatic inducible nitric oxide synthase, cyclooxygenase-2 and Bcl2, while mild expression of p53 and Bax were seen. Serum triglyceride and total cholesterol were significantly increased, while HDL-c was decreased in BPH. Interestingly, MeJA and finasteride (singly or combination) attenuated inflammatory indices and induced apoptotic parameters in BPH rats.
Conclusion |
MeJA protects against TP-induced BPH via mechanisms that involve anti-inflammation, induction of apoptosis and inhibition of phase I drug metabolizing enzyme.
Le texte complet de cet article est disponible en PDF.Keywords : Benign prostatic hyperplasia, Apoptosis, Inflammation, Methyl jasmonate
Plan
Vol 95
P. 1493-1503 - novembre 2017 Retour au numéro
Article précédent
- Sulforaphane prevents dexamethasone-induced muscle atrophy via regulation of the Akt/Foxo1 axis in C2C12 myotubes
- Young Hoon Son, Eun Jeong Jang, Young Woo Kim, Ju-Hee Lee
- Regulation of HOXA11-AS/miR-214-3p/EZH2 axis on the growth, migration and invasion of glioma cells
- Chenyang Xu, Tao He, Zhenjiang Li, Honglin Liu, Bingqian Ding
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?